Healthcare / BiotechnologyNasdaqGM
$27.54
-0.80 (-2.82%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-71.4M · quality 69.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
37/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$435M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-34.1%
↓Gross Margin
N/A
•Debt/Equity
0.04
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2012–2025 · 13 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.87x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-90.4M · FCF $-78.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||||
| Revenue | — | — | $925000.00 | — | — | — | — | — | $25.0M | — | — | — | — | — | — |
| Net Income | $-90.4M | $-90.4M | $-75.1M | $-36.3M | $-55.2M | $-60.7M | $-33.3M | $-69.4M | $-31.6M | $-50.2M | $-37.0M | $-21.9M | $-24.0M | $-8.7M | $-7.7M |
| EBITDA | $-87.3M | $-87.3M | $-71.9M | $-33.0M | $-52.0M | $-59.4M | $-32.9M | $-70.6M | $-32.3M | $-50.8M | — | — | — | — | — |
| EPS | — | — | -4.28 | -73.83 | -37.80 | -22.00 | -12.80 | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | -8930.3% | — | — | — | — | — | -130.5% | — | — | — | — | — | — |
| Net Margin | — | — | -8123.7% | — | — | — | — | — | -126.3% | — | — | — | — | — | — |
| Balance Sheet | |||||||||||||||
| Debt/Equity | 0.04 | 0.04 | 0.05 | 0.09 | -0.03 | — | — | — | — | — | — | — | — | — | — |
| Current Ratio | 13.08 | 13.08 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | |||||||||||||||
| Free Cash Flow | $-78.4M | $-78.4M | $-71.4M | $-51.7M | $-55.1M | $-50.8M | $-26.8M | $-16.3M | $-31.6M | $-45.2M | $-30.9M | — | — | — | — |
| Returns | |||||||||||||||
| ROE | -34.1% | -34.1% | -24.2% | -19.5% | 37.9% | 66.1% | -17.4% | -49.0% | -43.5% | -50.7% | -25.6% | -20.2% | -66.5% | 13.3% | 15.1% |
| Valuation | |||||||||||||||
| P/B | 1.61 | 1.61 | 1.31 | 0.57 | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | |||||||||||||||
| EPS Growth | — | — | 94.2% | -95.3% | — | -71.9% | — | — | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+61.9%
Start / end P/E
n/dx → n/dx
EPS bridge
-4.28 → n/d
Residual
+61.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.